Russia coronavirus vaccine more than 90 % effective, says Official

The Russian vaccine against the novel coronavirus has been effective in more than 90 per cent of individuals vaccinated in a trial study of 16,000 volunteers, the producer said on Wednesday.

Based on the numbers of those individuals who contracted the virus after being vaccinated or given a placebo, “the Sputnik V vaccine had an efficacy rate of 92 per cent,” the producer said in a statement.

That rate is on par with an experimental vaccine developed by U.S pharma giant Pfizer and German firm BioNTech, the trial results of which were announced earlier this week.

ALSO READ: Lai Mohammed keeps mum about #EndSARS frozen accounts, court case

Russia was the first country to approve its coronavirus vaccine for widespread use by the public, registering the Sputnik V vaccine in August.

Developed by the state’s Gamaleya research centre, the vaccine was named Sputnik after the world’s first man-made satellite, sent into orbit by the Soviet Union in the late 1950s, a triumph in the space race with rival superpower the United States.

(NAN)

YOU SHOULD NOT MISS THESE HEADLINES FROM NIGERIAN TRIBUNE

The All Progressives Congress (APC) has told a Federal High Court in Abuja, that the Comrade Adams Oshiomhole-led National Working Committee (NWC) was sacked to solve the internal leadership crises rocking the party.

The party also said that immediately the Caretaker/Extraordinary Convention Planning Committee was put in place after the NWC’s dissolution, the crises that had characterised its affairs were laid to rest.

 

Post COVID-19: Kano based industrialist tasks FG on economy 

A Kano based industrialist, Chief Kalu Ogbonnaya, has advised the Federal Government to take necessary steps to stimulate the nation’s economy to prevent a recession post COVID-19.

Ogbonnaya who spoke in an interview with the News Agency of Nigeria (NAN) on Thursday in Kano, said as a result of the coronavirus raving the world, no business has been moving.

You might also like
Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More